Niki BioSolutions, Inc., a Delaware corporation (the "Company," "Niki," "we," "our," or "us"), has entered into an at-the-market issuance sales agreement, dated October 9, 2026 (the "Sales Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright & Co., LLC," "Wainwright" or "Selling Manager") and Brookline Capital Markets, a division of Arcadia Securities, LLC ("Brookline," and together with Wainwright, the "Managers" and, each, a "Manager"), relating to the shares of common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may from time to time offer and sell shares of common stock, par value $0.0001 per share ("Common Stock"), having an aggregate offering price of up to $1,396,000 through Wainwright, acting as our selling manager.

This prospectus supplement should be read in conjunction with the accompanying prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the accompanying prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the accompanying prospectus, and any future amendments or supplements thereto.